An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS

Completed · Not applicable

Conditions studied: Cytomegalovirus Retinitis, HIV Infections

In brief

To evaluate the safety and tolerance of cidofovir (HPMPC) infusions in AIDS patients with relapsing cytomegalovirus (CMV) retinitis. To determine the time to retinitis progression in this patient population. To evaluate the impact of cidofovir therapy on visual acuity.

Key facts

Study ID

NCT00002142

Run by

Gilead Sciences

People needed

100

Last updated by the study team

2005-06-24

Who can join

Age: 13 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Concurrent Medication:
• Allowed:
• Antiretroviral agents.
• Oral trimethoprim/sulfamethoxazole.
• Aerosolized pentamidine.
• Dapsone.
• Fluconazole.
• Rifabutin.
• Filgrastim (G-CSF).
• Itraconazole.
• HIV vaccines.
• Patients must have:
• AIDS.
• CMV retinitis, with severity as specified in the Disease Status field.
• Life expectancy of at least 3 months.
• Consent of parent or guardian if less than 18 years of age.

You may not qualify if…

• Co-existing Condition:
• Patients with the following symptoms or conditions are excluded:
• Known clinically significant allergy to probenecid.
• Clinically significant cardiac disease, including symptoms of ischemia, congestive heart failure, or arrhythmia.
• Other active medical problems sufficient to hinder study compliance.
• Concurrent Medication:
• Excluded:
• Amphotericin B.
• Aminoglycoside antibiotics.
• Vidarabine.
• Intravenous pentamidine.
• CMV hyperimmune immunoglobulin.
• Other nephrotoxic or potentially nephrotoxic agents.
• Other investigational agents with anti-CMV activity.
• Ganciclovir.
• Intravenous or oral acyclovir (except following development of herpetic lesion).
• Foscarnet.
• Diuretics.
• Prior Medication:
• Excluded within 2 days prior to study entry:
• Ganciclovir or foscarnet.
• Excluded within one week prior to study entry:
• Amphotericin B.
• Aminoglycoside antibiotics.
• Vidarabine.

Where it is running

• Besselaar Associates — Princeton, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.